JOURNAL OF PHARMA INSIGHTS AND RESEARCH

REVIEW ARTICLE

Revolutionizing Therapeutics: The Power of Nanotechnology in Precision Medicine

Dipendra Kohar*[1], Dev Kumar Ray*[2], Rajip Nepal[3], Jyoti Phogat[4]

[1]*College of Pharmacy, B-Pharmacy, RIMT University (147301), Gobindgarh, Punjab, India.*
[2] *College of Pharmacy, B-Pharmacy, RIMT University (147301), Gobindgarh, Punjab, India.*
[3]*College of Pharmacy, B-Pharmacy, RIMT University (147301), Gobindgarh, Punjab, India.*
[4]*Research Scholar, MM College of pharmacy, Maharishi Markandeshwar (Deemed to be University), Mullana, Ambala- 133207, Haryana, India.*

Publication history: Received on 3 Sep 2023; Revised on 20 Oct 2023; Accepted on 25 Oct 2023

Article DOI: 10.5281/zenodo.10050246

Abstract: The use of Nanotechnology has provided scientific communities with novel therapeutic effects. It emphasizes how precision medicine incorporates the concepts of Nanoscience, with Nano carriers. Therapeutic compounds can be encapsulated by Nano carriers such as nanoparticles and liposomes, offering protection from degradation and enhancing pharmacokinetics. Nano systems' have customizable potential that enables the development of therapies specific to each patient's demands and illness features. Multifunctional carriers can directly affect immune reactions as well as overcome biological barriers and selectively target cells and tissues. Recently, research in the field of Nanotechnology has made remarkable advances. The present review emphasizes how disruptive nanotechnology has better therapeutic effect in cancer, neurology, and infectious illnesses and how it has the potential to transform pharmaceutical research and healthcare practices, enhancing patient quality and treatment results.
.

Keywords: Nanocarriers, Diseases; Multifunctional; Transformation; nanotechnology

1. Introduction

The term "nano" in the field of nanotechnology signifies a unit of measurement equivalent to one billionth (1 x 10^-9). Nanotechnology encompasses the study and manipulation of matter at a scale where its structures possess dimensions on the order of a billionth of a meter [1]. Recent advancements in multifunctional nanoparticles have opened new possibilities for the precise delivery of therapeutic compounds and imaging contrast agents to specific cell types. This has the potential to greatly enhance the effectiveness of treatments while minimizing any potential side effects. In the field of pharmaceuticals, nanoparticles are specifically defined as solid colloidal particles that range in size from 10 nm to 400 nm. These particles are composed of macromolecular materials that either dissolve, entrapped, or encapsulate the active agent (such as a drug or biologically active material), or have the active agent adsorbed or attached to them [2]. Technologies utilizing nanoscale substances have been employed to enhance the properties and develop novel functions for these substances. Numerous research projects are currently being conducted worldwide in this domain. In the medical field, nanotechnology has found diverse applications, including diagnosis, biosensors, and drug delivery. Consequently, this has led to the creation of innovative nanomedicines and nanodevices. To optimize the effects of a drug, the drug molecules must reach specific locations within the target tissue. However, due to the inability of drug molecules to selectively reach their site of action, there is a necessity for carriers that can efficiently deliver the required amount of the drug to its intended destination. The eye, particularly the posterior segment, poses challenges for drug penetration due to its structural peculiarities, such as the presence of a barrier function. As a result, extensive research studies focusing on nano-sized drug carriers have been conducted in the field of various types of cancers [3,4,5].



Figure 1 Structure of Liposomes

* Corresponding author: Dipender Kohar

2. Liposomess

Liposomes are closed vesicles (small lipid vesicles) composed of a phospholipid bilayer, and water-soluble drugs can be incorporated into their aqueous phase, whereas lipid-soluble drugs can be incorporated into their lipid phase [6]. The structure of Liposomes is illustrated in Figure 1. Liposomes have various advantages as drug carriers: (1) Because they are noncovalent aggregates, their lipid composition, size, and electric charge can be easily controlled [7,8]. Their modification, with surface polymers, carbohydrates, and antibodies, can be easily achieved to facilitate targeting;[9]. (3) Liposomes have almost no toxicity and low antigenicity; (4) Liposomes can be biodegradable and metabolized in vivo;[10]. (5) Properties such as membrane permeability can be controlled to some extent;[11]. and (6) Liposomes can hold various types of solutes with different properties and molecular weights, such as fat-soluble molecules, water-soluble molecules,[12] and amphiphilic molecules [13]. Because of these characteristics, studies have been conducted on the intravitreal injection of drug-bearing liposomes and have demonstrated that the release of the drug can be controlled, the half-life of the drug inside the vitreous body can be prolonged, and the toxicity of the drug can be reduced [14-19].

3. Nanostructured Lipid Carriers (NLCs)

Nanostructured lipid carriers (NLCs) are a type of drug-delivery system that consists of a core matrix composed of both solid and liquid lipids. These benefits include increased solubility, improved storage stability, enhanced permeability, and bioavailability, reduced adverse effects, prolonged half-life, and targeted delivery to specific tissues. As a result, NLCs have gained significant attention in recent years as a promising drug-delivery platform [20]. Solid lipid nanoparticles (SLNs) are derived from oil-in-water nanoemulsions, with the first generation developed in 1990 [21]. SLNs offer advantages like physio-logical lipids, organic solvent avoidance, large-scale production, improved bioavailability, drug protection, and controlled release characteristics as drug delivery carriers [22]. SLNs have drawbacks like unpredictable gelation, polymorphic transition, and low incorporation. Nanostructured lipid carriers (NLCs) were developed to address these issues, allowing for the avoidance of potential drawbacks like limited drug-loading capacity and storage expulsion. [23] Liposomes can be used as targeted drug carriers for different human tumours that increases patient compliance and reduces adverse effects [24].

4. Nanotechnology in precision medicine

Nanotechnology has emerged as a transformative force in the landscape of healthcare, catalyzing a paradigm shift towards precision medicine. Its significance lies in its capacity to revolutionize how diseases are diagnosed, treated, and understood. By operating at the nanoscale, it enables a level of precision that was previously unimaginable in medicine. Nanotechnology is not merely an incremental improvement; it represents a substantial departure from traditional one-size-fits-all medical approaches. It stands at the confluence of advanced science and innovative technology, offering a robust platform for addressing the complexities of individualized patient care and disease-specific treatments. The era of nanotechnology in precision medicine is marked by an exciting fusion of nanoscience, which explores the properties of matter at nanometer dimensions, and the practical application of nano carriers. This combination holds the key to the development of therapies that are not only tailored to specific diseases but also to the unique characteristics of each patient, heralding a new age of healthcare personalization [25-28].

Precision medicine, as facilitated by nanotechnology, places patients at the center of healthcare. It recognizes that diseases are as diverse as the individuals they afflict, and a one-size-fits-all approach often falls short. With nanotechnology, healthcare providers gain an unprecedented level of insight into the intricacies of diseases, right down to the molecular and cellular levels. This understanding equips them to craft treatments that are highly specific and finely tuned, resulting in more effective and less invasive therapies. Whether it's delivering medication directly to cancer cells, modulating immune responses with precision, or customizing treatment regimens based on a patient's genetic makeup, nanotechnology empowers healthcare practitioners to provide care that is not only more effective but also less prone to side effects. The implications are vast, with the potential to transform how diseases like cancer, neurodegenerative disorders, and infectious illnesses are managed, ultimately leading to better patient outcomes and enhanced quality of life. The journey into nanotechnology's role in precision medicine is a captivating one, where scientific innovation converges with patient-centric healthcare, offering a new dawn in medical practice [29-31].

5. Nano Carriers: Enabling Customized Therapies

Nanotechnology leverages a sophisticated toolkit of nano carriers to unlock the potential for truly customized therapeutic approaches. Among these, nanoparticles and liposomes have emerged as the workhorses of modern drug delivery. These carriers offer a remarkable ability to encapsulate therapeutic compounds, shielding them from premature degradation, and fine-tuning their pharmacokinetics. This capacity is invaluable in optimizing treatment efficacy while minimizing side effects. Nanoparticles, with their small size and customizable surface properties, can be tailored to carry a diverse range of therapeutic agents, including chemotherapeutic drugs, nucleic acids, and small molecules. Liposomes, on the other hand, are lipid-based carriers that excel in encapsulating both hydrophilic and hydrophobic compounds. Their versatility extends to not only drug delivery but also the targeted delivery of genetic material, making them integral in emerging fields like gene therapy. By facilitating controlled release and precise targeting, nano carriers have ushered in a new era of medicine that is tailored to the unique demands of each patient and the specific characteristics of their illness[31-32] .

The transformative potential of nano carriers is best illustrated through the lens of personalized medicine. As the shift towards patient-centric care gains momentum, the importance of tailored therapies becomes increasingly evident. Nano carriers provide the ideal platform for this transformation. By encapsulating therapeutic agents within nano carriers, it becomes possible to adjust drug release profiles, ensuring medications are administered precisely when and where they are needed. This has significant implications for conditions like cancer, where minimizing damage to healthy cells while delivering therapy directly to tumor sites is of paramount importance. Nano carriers can be engineered to navigate biological barriers, including the blood-brain barrier, offering newfound hope in the treatment of neurodegenerative diseases that were once considered impenetrable. In essence, nano carriers offer a level of customization and precision that was inconceivable in traditional drug delivery methods. They represent a cornerstone of the evolving landscape of personalized medicine, where treatments are tailored to individual needs, ultimately improving therapeutic outcomes and patient quality of life [33].

6. Multifunctional Carriers: Pioneering Immunotherapy and Targeted Therapies

Multifunctional carriers stand at the forefront of innovative therapeutic strategies, particularly in the domains of immunotherapy and targeted therapies. These carriers are engineered to be versatile and responsive, capable of modulating immune responses and precisely targeting cells and tissues. In the realm of immunotherapy, multifunctional carriers have ushered in a new era of treatment for conditions like cancer and autoimmune disorders. By integrating immunomodulatory agents within these carriers, they can be directed to enhance or suppress immune reactions, offering a tailored approach to immune-related diseases. In the context of targeted therapies, multifunctional carriers possess the remarkable ability to navigate biological barriers, ensuring that therapeutic agents reach their intended destination. These carriers are not bound by traditional limitations, as they can be designed to transport therapies across the formidable blood-brain barrier or other selective barriers, offering new hope for treating neurodegenerative conditions and previously hard-to-reach disease sites. As a result, multifunctional carriers are pioneering a new era of medicine, one that is highly tailored and efficacious, improving the precision of therapy and patient outcomes [34].

The versatility of multifunctional carriers extends across a spectrum of diseases. They can be adapted to deliver a wide range of therapies, from small molecules and biologics to genetic material and nanoparticles. This adaptability is particularly promising in the context of cancer therapy, where precision is of paramount importance. By equipping multifunctional carriers with tumor-targeting ligands or imaging agents, they can home in on cancer cells with pinpoint accuracy, reducing collateral damage to healthy tissues. Moreover, their applications extend to autoimmune disorders, where modulating immune responses plays a critical role in managing these conditions. Through precise control over immunotherapeutic agents, multifunctional carriers offer more efficient and targeted treatments for autoimmune diseases. As our understanding of the interplay between the immune system and disease deepens, multifunctional carriers represent a dynamic frontier in personalized medicine, fostering new therapeutic possibilities and ultimately improving the quality of care for a broad spectrum of medical conditions [35, 36].

7. Transformative Potential of Nanotechnology in Healthcare - Nanotechnology Advancements in Disease Treatment

In recent years, the field of nanotechnology has witnessed remarkable advancements that hold the promise of revolutionizing disease treatment. These advancements span a wide spectrum of medical disciplines, from oncology to neurology and infectious diseases. Nanotechnology has enabled more precise, targeted, and effective therapies, fundamentally altering the landscape of disease management. One of the most profound impacts of nanotechnology is seen in the treatment of cancer. Nano carriers, such as nanoparticles and liposomes, are engineered to deliver anti-cancer agents directly to tumor sites, sparing healthy tissues from the ravages of chemotherapy. The results are not only improved survival rates but also a higher quality of life for cancer patients. In neurology, the formidable blood-brain barrier, which has posed a significant challenge in treating brain disorders, is being breached with the help of nanotechnology. This opens up new possibilities for the treatment of neurodegenerative diseases, potentially slowing down disease progression and enhancing patients' cognitive functions. Additionally, the use of nanotechnology in the management of infectious diseases is particularly promising. Nano carriers like nanoemulsions are serving as effective vaccine carriers, offering a novel approach to preventing and treating infectious illnesses. These groundbreaking achievements underscore the transformative potential of nanotechnology in the field of healthcare [37].

The impact of nanotechnology in disease treatment extends beyond delivering therapeutic agents. It encompasses a broader integration of diagnostic technologies, enabling more personalized treatment approaches. With the marriage of diagnostics and nanotechnology, a new era of personalized medicine is unfolding. In this paradigm, patients receive treatments and therapies that are tailored to their specific genetic, molecular, and cellular profiles. This not only improves the efficacy of treatments but also minimizes side effects, providing a significant boost to patient quality of life. The convergence of diagnostics and nanotechnology fosters a deeper understanding of disease mechanisms, paving the way for innovative therapeutic strategies. Moreover, the potential of nanotechnology reaches into areas such as food and dietary supplements. By integrating nanotechnology into these domains, the stability and effectiveness of food-based treatments can be significantly enhanced, ensuring that patients receive the full benefit of these interventions. As the field of nanotechnology in healthcare continues to evolve, the future holds exciting prospects for nanoscale medicine delivery methods that have the potential to further improve healthcare and overall well-being, fostering a new frontier in medical practice [38].

8. Conclusion

In conclusion, the transformative influence of nanotechnology in healthcare is undeniable. It heralds a new era of precision medicine, where nanoscience and innovative nano carriers reshape therapeutic approaches. By enabling customized therapies through nano carriers, nanotechnology offers more effective, patient-specific treatments with minimal side effects. Multifunctional carriers pioneer immunotherapy and targeted therapies, expanding their applications across various diseases. Notably, nanotechnology advancements in cancer, neurology, and infectious diseases are revolutionizing treatments, promising better outcomes. The integration of diagnostics and nanotechnology drives personalized medicine, while the potential to enhance food and dietary supplements suggests a brighter future. This dynamic field of nanotechnology in healthcare opens unprecedented horizons for improved well-being and patient care.

References

1. Poole CP, Owens FJ. Introduction to nanotechnology.
2. Muthu MS, Singh S. Targeted nanomedicines: effective treatment modalities for cancer, AIDS and brain disorders.
3. Sahoo SK, Labhasetwar V. Nanotech approaches to drug delivery and imaging. Drug discovery today. 2003 Dec 15;8(24):1112-20.
4. Gaudana R, Ananthula HK, Parenky A, Mitra AK. Ocular drug delivery. The AAPS journal. 2010 Sep; 12:348-60.
5. Liu S, Jones L, Gu FX. Nanomaterials for ocular drug delivery. Macromolecular bioscience. 2012 May;12(5):608-20.
6. Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science. 2004 Mar 19;303(5665):1818-22.
7. Bangham AD, Horne RW. Negative staining of phospholipids and their structural modification by surface-active agents as observed in the electron microscope. Journal of molecular biology. 1964 Jan 1;8(5):660-IN10.
8. Oku N. Anticancer therapy using glucuronate-modified long-circulating liposomes. Advanced drug delivery reviews. 1999 Nov 10;40(1-2):63-73.
9. Sapra P, Tyagi P, Allen TM. Ligand-targeted liposomes for cancer treatment. Current drug delivery. 2005 Oct 1;2(4):369-81.
10. Van Rooijen N, van Nieuwmegen R. Liposomes in immunology: multilamellar phosphatidylcholine liposomes as a simple, biodegradable and harmless adjuvant without any immunogenic activity of its own. Immunological communications. 1980 Jan 1;9(3):243-56.
11. LOPEZ-BERESTEIN GR, Mehta R, Hopfer R, Mehta K, Hersh EM, Juliano R. Effects of sterols on the therapeutic efficacy of liposomal amphotericin B in murine candidiasis. Cancer Drug Delivery. 1983;1(1):37-42.
12. Oku N, Nojima S, Inoue K. Selective release of non-electrolytes from liposomes upon perturbation of bilayers by temperature change or polyene antibiotics. Biochimica et Biophysica Acta (BBA)-Biomembranes. 1980 Jan 25;595(2):277-90.
13. Klibanov AL, Maruyama K, Torchilin VP, Huang L. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS letters. 1990 Jul 30;268(1):235-7.
14. Tremblay C, Barza M, Szoka F, Lahav M, Baum J. Reduced toxicity of liposome-associated amphotericin B injected intravitreally in rabbits. Investigative ophthalmology & visual science. 1985 May 1;26(5):711-8
15. Barza M, Baum J, Tremblay C, Szoka F, D'Amico DJ. Ocular toxicity of intravitreally injected liposomal amphotericin B in rhesus monkeys. American journal of ophthalmology. 1985 Aug 1;100(2):259-63.
16. Fishman PH, Peyman GA, Lesar T. Intravitreal liposome-encapsulated gentamicin in a rabbit model. Prolonged therapeutic levels. Investigative ophthalmology & visual science. 1986 Jul 1;27(7):1103-6.
17. PEYMAN GA, KHOOBEHI B, TAWAKOL M, SCHULMAN JA, MORTADA HA, ALKAN HA, FISCELLA R. Intravitreal injection of liposome-encapsulated ganciclovir in a rabbit model. Retina. 1987 Dec 1;7(4):227-9.
18. Peyman GA, Schulman JA, Khoobehi BA, Alkan HM, Tawakol ME, Mani HA. Toxicity and clearance of a combination of liposome-encapsulated ganciclovir and trifluridine. Retina (Philadelphia, Pa.). 1989 Jan 1;9(3):232-6.

19. Bochot A, Fattal E, Boutet V, Deverre JR, Jeanny JC, Chacun H, Couvreur P. Intravitreal delivery of oligonucleotides by sterically stabilized liposomes. Investigative Ophthalmology & Visual Science. 2002 Jan 1;43(1):253-9.
20. Fang CL, A Al-Suwayeh S, Fang JY. Nanostructured lipid carriers (NLCs) for drug delivery and targeting. Recent patents on nanotechnology. 2013 Jan 1;7(1):41-55.
21. Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery–a review of the state of the art. European journal of pharmaceutics and biopharmaceutics. 2000 Jul 3;50(1):161-77.
22. Jores K, Mehnert W, Mäder K. Physicochemical investigations on solid lipid nanoparticles and on oil-loaded solid lipid nanoparticles: a nuclear magnetic resonance and electron spin resonance study. Pharmaceutical research. 2003 Aug;20:1274-83.
23. Müller RH, Radtke M, Wissing S. Nanostructured lipid matrices for improved microencapsulation of drugs. International journal of pharmaceutics. 2002 Aug 21;242(1-2):121-8.
24. Hofheinz RD, Gnad-Vogt SU, Beyer U, Hochhaus A. Liposomal encapsulated anti-cancer drugs. Anti-cancer drugs. 2005 Aug 1;16(7):691-707.
25. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA: a cancer journal for clinicians. 2005 Mar;55(2):74-108.
26. Mulcahy N. Cancer to become leading cause of death worldwide by 2010 by Medscape Medical News© 2008.
27. Nataru S, Pulicherla Y, Gaddala B. A review on medicinal plants as a potential source for cancer. Int J Pharm Sci Rev Res. 2014;26(1):235-48.
28. Wilkinson L, Gathani T. Understanding breast cancer as a global health concern. The British Journal of Radiology. 2022 Feb 1;95(1130):20211033.
29. Subedi R, Dhimal M, Budukh A, Chapagain S, Gyanwali P, Gyawali B, Dahal U, Dikshit R, Jha AK. Epidemiologic pattern of cancer in Kathmandu Valley, Nepal: Findings of population-based cancer registry, 2018. JCO Global Oncology. 2021 Mar;7(1):443-52.
30. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2021 May;71(3):209-49.
31. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2018 Nov;68(6):394-424.
32. Bhat AH. Prevalence Estimates and Associated Risk Factors of Cancer in India: An Analytical Review.
33. Reddy VA, Sarin R, Panda D, Hanitha RN, Jain J, Chatterjee S, Annapurneswari S, Saipillai MZ, Gupta S, Khan E, Bhattacharya J. A Multi-centric retrospective study into the epidemiological distribution of breast cancer patients in India. Journal of Cancer Research and Therapeutics. 2023 Jul 19.
34. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. Journal of clinical oncology. 2023 Mar 20;41(9):1638-45.
35. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New England journal of medicine. 2001 Mar 15;344(11):783-92.
36. Batist G, Ramakrishnan G, Rao CS, Chandrasekharan A, Gutheil J, Guthrie T, Shah P, Khojasteh A, Nair MK, Hoelzer K, Tkaczuk K. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. Journal of Clinical Oncology. 2001 Mar 1;19(5):1444-54.
37. O'Brien ME, Wigler N, Inbar MC, Rosso R, Grischke E, Santoro A, Catane R, Kieback DG, Tomczak P, Ackland SP, Orlandi F. Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl (CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer. Annals of oncology. 2004 Mar 1;15(3):440-9.
38. Shenoy DB, Amiji MM. Poly (ethylene oxide)-modified poly (ε-caprolactone) nanoparticles for targeted delivery of tamoxifen in breast cancer. International journal of pharmaceutics. 2005 Apr 11;293(1-2):261-70.

Author's short biography

Dipendra Kohar:

I am Dipendra Kohar, currently pursuing my Bachelor of Pharmacy (B Pharmacy) in the 7th semester at the College of Pharmacy, Rimt University, Punjab.

Dev Kumar Ray:

I am Dev kumar Ray, currently pursuing my Bachelor of Pharmacy (B Pharmacy) in the 7th semester at the College of Pharmacy, Rimt University, Punjab..

Rajip Nepal:

I am Rajip Nepal, currently pursuing my Bachelor of Pharmacy (B Pharmacy) in the 7th semester at the College of Pharmacy, Rimt University, Punjab..

Jyoti Phogat:

I am Jyoti Phogat, currently pursuing Ph.D. (Pharmaceutics) at the college of pharmacy, M.M University Mullana Ambala.